Life Biosciences Begins Human Trial of Anti‑Aging Eye Drug ER‑100

Boston‑based Life Biosciences has initiated a Phase 1 clinical trial of ER‑100, a drug that uses partial epigenetic reprogramming to reverse cellular aging. The study, cleared by the U.S. FDA, will enroll roughly 18 adults with glaucoma or non‑arteritic anterior ischemic optic neuropathy (NAION) to assess safety and early efficacy, aiming to restore damaged retinal ganglion cells. The therapy employs three proteins (OSK) to reactivate youthful epigenetic instructions, a concept championed by co‑founder David Sinclair, who said the trial “represents the first opportunity to test whether restoring that information can ameliorate human disease.”